至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC

Cancers (Basel). 2022-03; 
Carolyn M Jablonowski, Hyea Jin Gil, Emilia M Pinto, Prahalathan Pichavaram, Andrew M Fleming, Michael R Clay, Dongli Hu, Christopher L Morton, Shondra M Pruett-Miller, Baranda S Hansen, Xiang Chen, Karissa M Dieseldorff Jones, Yanling Liu, Xiaotu Ma, Jun Yang, Andrew M Davidoff, Gerard P Zambetti, Andrew J Murphy
Products/Services Used Details Operation
Gene Synthesis … The present study hypothesized that WT1 and N-MYC could regulate TERT expression in Wilms … (Genscript Biotech) to include two E box motifs which constitute N-MYC binding sites. … Get A Quote

摘要

Increased mRNA is associated with disease relapse in favorable histology Wilms tumor (WT). This study sought to understand the mechanism of increased expression by determining the association between and WT1 and N-MYC, two proteins important in Wilms tumor pathogenesis that have been shown to regulate expression. Three out of 45 (6.7%) WTs and the corresponding patient-derived xenografts harbored canonical gain-of-function mutations in the promoter. This study identified near ubiquitous hypermethylation of the promoter region in WT compared to normal kidney. WTs with biallelic inactivating mutations in (7/45, 15.6%) were found to have lower expression by RNA-seq and qRT-PCR and lower telomerase activity... More

关键词

MYCN, N-MYC, TERT, WT1, Wilms tumor, anaplasia, blastema, kidney, telomerase